Vancomycin therapy in secondary care; investigating factors that impact therapeutic target attainment - 18/04/17
Doi : 10.1016/j.jinf.2016.12.011
Timothy M. Rawson ⁎ 
, Esmita Charani
, Esmita Charani National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, United Kingdom
∗Corresponding author. Hammersmith Hospital, Du Cane Road, London, W12 0HS, United Kingdom.Hammersmith HospitalDu Cane RoadLondonW12 0HSUnited Kingdom
Luke S.P. Moore
National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, United Kingdom
Imperial College Healthcare NHS Trust, Du Cane Road, London, W12 0HS, United Kingdom
Pau Herrero
Department of Electrical and Electronic Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, United Kingdom
Ji Soo Baik
School of Medicine, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK
Akash Philip
Department of Electrical and Electronic Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, United Kingdom
Mark Gilchrist , Eimear T. Brannigan
, Eimear T. Brannigan Imperial College Healthcare NHS Trust, Du Cane Road, London, W12 0HS, United Kingdom
Pantelis Georgiou
Department of Electrical and Electronic Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, United Kingdom
William Hope
Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, L69 3GE, United Kingdom
Alison H. Holmes
National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, United Kingdom
Imperial College Healthcare NHS Trust, Du Cane Road, London, W12 0HS, United Kingdom
Keywords : Vancomycin, Obesity, Antimicrobial resistance, Pharmacokinetic–pharmacodynamic, Population modelling
Le texte complet de cet article est disponible en PDF.
Plan
© 2016
The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 74 - N° 3
P. 320-324 - mars 2017 Retour au numéro
Article précédent
- Measles – A tale of two sisters, vaccine failure, and the resurgence of an old foe
- Aleem Ahmed, Amandip Sahota, Iain Stephenson, Kevin E. Brown, Julian W. Tang
- Comparison of in vitro synergy of various ?-lactams with vancomycin against methicillin-resistant Staphylococcus aureus
- Chun-Hsing Liao, Shey-Ying Chen, Yu-Tsung Huang, Hsih-Yen Tsai, Po-Ren Hsueh
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?